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Abstract
A panel of biomarkers may improve predictive performance over individual markers. Although
many biomarker panels have been described for ovarian cancer, few studies used pre-diagnostic
samples to assess the potential of the panels for early detection. We conducted a multi-site
systematic evaluation of biomarker panels using pre-diagnostic serum samples from the Prostate,
Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial.
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Using a nested case-control design, levels of 28 biomarkers were measured laboratory-blinded in
118 serum samples obtained before cancer diagnosis and 951 serum samples from matched
controls. Five predictive models, each containing 6–8 biomarkers, were evaluated according to a
pre-determined analysis plan. Three sequential analyses were conducted: blinded validation of
previously established models (Step 1); simultaneous split-sample discovery and validation of
models (Step 2); and exploratory discovery of new models (Step 3). Sensitivity, specificity,
sensitivity at 98% specificity, and AUC were computed for the models and CA125 alone among
67 cases diagnosed within one year of blood draw and 476 matched controls. In Step 1, one model
showed comparable performance to CA125, with sensitivity, specificity and AUC at 69.2%,
96.6% and 0.892, respectively. Remaining models had poorer performance than CA125 alone. In
Step 2, we observed a similar pattern. In Step 3, a model derived from all 28 markers failed to
show improvement over CA125.
Thus, biomarker panels discovered in diagnostic samples may not validate in pre-diagnostic
samples; utilizing pre-diagnostic samples for discovery may be helpful in developing validated
early detection panels.
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Introduction
Ovarian cancer is the fifth leading cause of cancer death among women in the US. While
early detection might reduce ovarian cancer mortality, there is currently no proven effective
early detection tool for the disease.
In the last decade, many serum biomarkers or panels of biomarkers have been reported to
detect ovarian cancer with higher sensitivity and specificity than the best marker currently
available, CA125 (1–4). With one exception (5), such studies utilized serum samples
collected at the time of diagnosis, and generally included a high proportion of cases with
advanced stage disease. Further, few of these biomarkers or panels have been evaluated in a
rigorous validation study. Thus, their utility for screening, which requires detection at an
asymptomatic phase, cannot be determined. This general scenario is not limited to ovarian
cancer – for virtually all of the major cancers, many promising predictive biomarkers have
been identified, but few have been tested rigorously in pre-diagnostic specimens (specimens
collected before clinical manifestation of the disease from asymptomatic subjects).
This report is the second of two companion reports describing a multi-site, simultaneous,
coordinated effort to systematically evaluate the performance of biomarkers for early
detection of ovarian cancer using a nested case-control design and stored, pre-diagnostic
serum samples obtained from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer
Screening Trial. The first report details the developmental process for selecting the best
biomarkers from phase II (diagnostic) and phase III (pre-diagnostic) specimens to be
included in a final panel of biomarkers from a larger pool of candidate markers (6). This
report proposes a novel, systematic approach for un-biased evaluation of classification
models combining multiple biomarkers and presents the performance results in pre-
diagnostic samples of five predictive models derived from the first report.
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Materials and Methods
PLCO Biorepository
The pre-diagnostic serum samples used in the current study were from the PLCO
biorepository. PLCO is a randomized controlled cancer screening trial evaluating various
screening tests for the four PLCO cancers. Over 150,000 healthy subjects ages 55–74 from
across the U.S. were randomized to a screening or usual care arm at ten screening sites from
1993 to 2001. The primary outcome of the trial is to assess whether routine screening can
reduce cancer-specific mortality (7,8). The overall screening protocol has been described
elsewhere (8). For ovarian cancer screening, women with at least one ovary at baseline
received a CA125 blood test at each of six annual screenings, and a transvaginal ultrasound
(TVU) at the first four screenings (9). Subjects who tested positive for either CA125 or TVU
were referred to their local physicians who determined the diagnostic workup procedures.
Any diagnosis of cancer and its stage, grade, and initial treatment, were obtained. Subjects
with positive tests but no cancer diagnosis continued to undergo annual screenings. Cancers
diagnosed in between screens, or after the screening period ended, were identified through
annual surveys of cancer and vital status. Data on demographics, risk factors and dietary
information were collected through multiple questionnaires administered at baseline and
during the follow up period.
Blood samples were collected from intervention arm subjects at each of the six annual
screens (10). Therefore, up to six serial bloods may be available for a given subject. The
collection of biospecimens was approved by the NCI Special Studies Institutional Review
Board (OH97-C-N041) and by the local Institutional Review Board for each of the screening
sites. Informed consent was obtained from all subjects who provided blood samples to be
stored for future research. Blood samples were processed in several different ways to obtain
serum, plasma, buffy coat, red blood cells, or cryo-preserved whole blood.
Study Coordination
Six investigator groups participated in this study; each group’s proposal was approved by
the PLCO Etiologic and Early Marker Studies (EEMS) Review Panel1, on the basis of
scientific merits, to use PLCO pre-diagnostic specimens to evaluate a panel of biomarkers
for early detection of ovarian cancer. The specific markers included in each panel are shown
in Table 1. The rationale for selecting these markers is detailed in the companion report (6).
Most of these markers had been previously shown to differentiate clinical cases from control
subjects with high sensitivity and specificity (2–5,11–13).
The NCI PLCO leadership assumed overall coordination of these studies, with the
investigators’ consent, input and collaboration, in order to standardize sampling, statistical
methods, and data interpretation across the studies.
Common sampling plan—Figure 1 shows the subject selection criteria. Among 24,650
eligible subjects, 118 cases of pathologically confirmed (through May 2006) invasive
ovarian, primary peritoneal, and fallopian tube cancers with appropriate consents and
available samples were identified. Both screen-detected cases (identified from diagnostic
workup subsequent to a positive CA125 or TVU test), and clinically diagnosed cases were
included. For each case, eight controls were randomly selected from 24,473 healthy subjects
without cancer: four general population controls, 2 controls with a family history of breast or
ovarian cancers, and two controls with elevated CA125. These special controls were
1More information about access to PLCO biorepository resource is available on the website www.plcostars.com or plco.cancer.gov
(note that this is a resource for studying many cancers, not just prostate, lung, colorectal, and ovarian cancers).
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included to assess the performance of the models in high risk populations but were not
included in primary analyses. Controls were frequency-matched by age and calendar year of
blood draw. For each study subject, a single serum sample closest and prior to diagnosis
(proximate sample) was selected for laboratory analysis.
Common data analysis plan—The common data analysis plan was formulated to
clearly distinguish between validation and discovery, both of which were to be
accommodated in the overall analysis strategy. In this study, validation refers to “hypothesis
testing”, i.e. the assessment of a “locked-in” marker panel and classification model
conducted on blinded samples. A stepwise analytic plan, as described below, was developed
to accommodate the multiple study goals (i.e. validation and discovery), while ensuring
uniformity in study conduct and data interpretation.
Step 1: Validation of previously established models: Step 1 was designed to determine the
performance of each marker panel and associated classification model that was pre-
established in diagnostic samples. Each investigator team was required to predict case/
control status on each sample, using the classification model. The predictions, along with
individual marker values and description of the model, were submitted to PLCO so that the
PLCO statistician could calculate performance indicators for each marker panel on behalf of
the investigators, who would remain blinded to the samples throughout the entire process.
Step 2: Simultaneous discovery and validation of models: Step 2 was designed to
determine whether models tested in Step 1 could be improved if investigators were given the
opportunity to train (discover) on a subset of the PLCO pre-diagnostic samples and
subsequently validate on the remaining blinded samples. Upon completion of Step 1, the
data set was thus randomly split 50–50 (done by a third party programmer who was not
involved in the data analysis) into a training set (60 cases and 476 controls), which was
subsequently unblinded, and a validation set (58 cases and 475 controls), which remained
blinded. Covariates associated with the samples, including demographic, lifestyle, medical
history and other common risk factors such as hormone use status were made available at
this point for model building. As in Step 1, investigators were required to predict the case/
control status of each sample in the validation set. Prediction models were based on 60 cases
and 239 general population controls in the training set. The predictions, along with the
modified classification model, were submitted to the PLCO statistician for computation of
performance measures as in Step 1. Note that investigators were not provided their Step 1
results until after Step 2 had been completed to ensure total blinding.
Step 3: Exploratory discovery of new models: Step 3 was for discovery of new panels and
models. At this time, PLCO released (un-blinded) the full dataset to all investigator teams so
that they could further refine panels and models by training on the entire sample set2. This
approach increased the sample size and study power, but it did not provide an opportunity
for validation in an independent sample set within PLCO. We report here the results of a
single family of logistic models developed on the pooled set of markers across all sites
(“pan-site model”). The fixed subset of markers used across this family was determined
based on performance over all 118 cases and 476 general population controls; distinct
individual models in the family corresponded to different intervals from blood draw to
diagnosis (e.g., ≤ 1 year, 1–2 years) and were fit on these cases and all general population
controls.
2Some investigator teams wished to remain blinded to the validation set for future studies. In this case, the full dataset was released to
a statistician designated by the team.
Zhu et al. Page 4
Cancer Prev Res (Phila). Author manuscript; available in PMC 2012 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Statistical methods
The primary performance measures were agreed upon a priori; these included sensitivity,
specificity, area under the Receiver Operating Characteristic (ROC) curve (AUC), and
sensitivity at 98% specificity (SE98). Note the latter two measures could be computed only
for those models that produced a propensity score (i.e., a one dimensional quantity in which
increasing values indicate a greater likelihood of disease). For comparison, all of these
measures were also computed for CA125 alone (using the PLCO trial cutoff of ≥35 U/ml).
Performance measures for the Step 1 models (and the Step 3 model) were computed for both
the training and validation data sets, whereas performance measures for the Step 2 models
were computed for the validation set only. However, to facilitate direct comparison of Step 1
and Step 2 models, we also computed the Step 1 performance measures limited to what
became the validation set in Step 2. For three of the panels (A, C, D), both the Step 1 and 2
models incorporated propensity scores; thus each allowed for computation of AUC and
SE98. For these, we directly compared AUC and SE98 across each step and tested the null
hypothesis of no difference between the steps; for AUC, the statistical test accounted for the
fact that the AUCs at the two steps were correlated (14). The remaining two models (B, E)
incorporated a propensity score at only Step 1 or Step 2. For these we could not compare
AUC or SE98 across steps; however, we could compare the sensitivity at the fixed level of
specificity (e.g. X%) achieved by the model without the propensity score. Specifically, we
adjusted the propensity score of the model with such a score to find a cutoff that gave a
specificity of X and then computed the corresponding sensitivity of the model at that cutoff.
Results
Table 1 shows the markers assayed and their inclusion in the models for Step 1 through Step
3. Note that two investigator groups (MDACC and NCI DCEG) had independently
developed the same panel, resulting in five distinct marker panels3. A total of 28 individual
biomarkers were assayed. CA125 was included in all panels, and HE4 was included in 3 of
the 5 panels. The pan-site (Step 3) model included CA125, HE4, CA72.4, SLPI, and B2M.
The Step 1 and Step 2 models ranged from linear combinations of log marker values to
highly non-linear expressions incorporating the maximum of a set of normalized marker
values. One model (B2) incorporated family history of breast and ovarian cancer and
smoking status in addition to marker values. Detailed description of each model is provided
in Supplemental Materials.
Table 2 shows the demographic features of all cases and controls originally selected for this
study. All subjects were 55 or older (by design) and most were white.
Although 118 cases were originally included in the study, the interval from the date of the
sample (blood draw) to diagnosis varied widely, ranging from 12 to 2898 days, with a
majority (N=67, 57%) being less than one year. For the purpose of comparing the
performance of the models to each other and to CA125 alone, we restricted our analysis to
the 67 cases within one year and 26 cases 1–2 years of diagnosis. Table 3 shows the
distribution of histologic type, stage and grade of these cases. Additionally, only the general
population controls were used for the main analyses.
3This overlap was not identified until the marker data had been submitted to PLCO, due to the complexity of the project, and the fact
that the markers eventually measured were somewhat different from those originally proposed. Both panels were measured using the
same ProteinChip platform developed by Vermillion. Correlation coefficients between the MDACC and NCI DCEG data for the same
marker ranged from 0.22 (APOA1) to 0.94 (ITIH4). The PIs agreed to jointly represent the panel (based on MDACC dataset) in this
report.
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Table 4 displays the results for the five models for Steps 1 and 2. For the within-one-year
cases, one model (B1) had comparable performance to CA125 alone in Step 1, with
sensitivity, SE98, specificity, and AUC of 69.2%, 64.6%, 96.6% and 0.892, respectively,
compared to 63.1%, 64.6%, 98.5% and 0.890 for CA125. Three of the models (A1, C1, E1)
showed substantially lower sensitivity (34.3% to 37.9%), SE98 (25.4% to 32.8%) and AUC
(0.712 to 0.721) than CA125. Finally, one model (D1) employed a low cutoff, resulting in
very low specificity (32.2%) but high sensitivity (95.4%); AUC (0.858) and SE98 (52.3%)
were slightly lower than that of CA125. In Step 2, we observed the same general pattern as
in Step 1 in the within-one-year cases, with one model (B2) performing comparably to
CA125 alone and the remaining models showing overall lower performance. Figure 2
compares the receiver operating characteristic (ROC) curves for the models, CA125 and the
Step 3 pan-site model. For the 1–2 year cases, sensitivity ranged from 0% to 21.4% for the
models and 0% for CA125 alone.
Table 5 displays direct comparisons of the performance of the Step 1 and Step 2 models for
each panel for the within-one-year cases. For the three panels (A, C & D) where the AUC
could be computed at both steps, AUC was statistically significantly improved in two of the
panels (with an increase of about 0.10) but was significantly worsened in the other panel
(decrease of about 0.10). For the other two panels (B & E), sensitivity at fixed specificity
was slightly lower at Step 2 than Step 1.
The Step 3 model showed an AUC of 0.911 and a SE98 of 68.2% in the within-one-year
cases (Table 4). Its performance in these cases was only slightly, and not statistically
significantly, better than both that of CA125 alone and that of the best performing Step 1 or
2 model, namely B1. For the 1–2 year cases, the AUC of the model was 0.740, compared to
0.642 for CA125 (p=0.14) (not shown in Table 4).
We also examined the performance of each prediction model in high risk women using the
special controls (data not shown). None of the models (at Step 1 or 2) displayed a significant
difference in specificity (or sensitivity) between women who reported a family history of
breast or ovarian cancer and those who did not. We also observed that, all models except E1
and E2 showed significantly decreased specificity (and significantly increased sensitivity) in
women with elevated CA125 compared to those with normal CA125.
Discussion
The importance of using appropriate specimens for biomarker research at all stages has
gained much attention in recent years, largely due to the fact that many enthusiastic reports
of promising biomarkers have turned out not to be reproducible. This phenomenon has been
examined by numerous investigators (15–20). One of the major problems is bias introduced
by systematic differences between the case and control specimens used for biomarker
discovery that inflates the performance of the markers for cancer diagnosis (21–24).
In 2008, Pepe et al described the PRoBE (prospective-specimen collection, retrospective-
blinded-evaluation) design to “eliminate common biases that pervade the biomarker research
literature" (25). In the PRoBE approach, a "case-control" analysis is conducted among
subjects followed in a cohort study with prospectively collected specimens. Many potential
biases are prevented when specimens are collected and handled in a "blinded" manner,
before the diagnosis is known. The current PLCO analysis, designed before the PRoBE
approach was described, utilized essentially the same approach.
The idea that a panel of biomarkers could perform significantly better than individual
biomarkers alone has gained popularity in recent years. A number of studies have shown
improved performance of a panel of ovarian cancer biomarkers over CA125 alone (26–28)
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when used in diagnostic samples. Contrary to these reports, the current study found that the
inclusion of additional biomarkers appeared to add little to CA125 when used in pre-
diagnostic samples.
The current study is significant in several ways. First, it provides the first example of a
coordinated, systematic approach to biomarker validation using pre-diagnostic samples.
Second, the findings raise a question about the current paradigm for biomarker development,
namely, using diagnostic samples for discovery and validating them in pre-diagnostic
samples. It is possible that markers discovered in diagnostic samples are significantly
differentially expressed only when the tumor becomes large, or clinically apparent. Such
markers may have little value for early detection.
As mentioned in the companion paper (6), the fact that screening with CA125 was ongoing
at the time of the blood draws may have affected the resulting estimates of the sensitivity
(and AUC) of CA125, especially with regard to the more-than-one-year cases. Specifically,
subjects with elevated CA125 tended to be diagnosed within one year of blood draw due to
follow up of the PLCO screening; thus such cases were selectively excluded from the pool
of more-than-one-year cases. Indeed, the sensitivity of CA125 in the 13–24 month cases
here was exactly zero (using the PLCO cutoff of 35 U/ml). Since each of the models
described here incorporates the CA125 level, the ongoing screening may have also affected
the estimates of their performance, although probably not to as great an extent. For the
purpose of comparing the performance of the models to that of CA125 alone, we believe
that the results restricted to the within-one-year cases provide for a reasonably unbiased
assessment. For cases further removed from the blood draw, including the 13–24 month
cases, however, the comparison may be somewhat biased in favor of the models
As a next step, it is possible that incorporating longitudinal marker values obtained from
serial samples may improve the performance of a marker or a panel of markers. It has been
shown that utilizing serial CA125 values improved its performance (29). To this end, two of
the current investigator teams have already been approved to use the PLCO serial samples to
further evaluate their marker panels and models.
A lesson learned from this exercise is that more attention needs to be directed toward
biomarker discovery. A critical aspect of study design should be choosing the appropriate
specimens according to the intended use of the biomarker. For biomarkers of early disease,
it may be necessary to use pre-diagnostic samples for discovery. We hope this study serves
as a catalyst for further discussions on how to move the biomarker field forward toward
clinical applications.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Sampling scheme. Note: 119 cases and 952 controls were originally selected following the
sampling scheme. One case was excluded due to a coding error, and one control was
excluded due to a consent issue, leaving 118 cases and 951 controls in the final sample set.
LMP denotes tumors of low malignant potential.
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Figure 2.
Receiver operating characteristic (ROC) curves for Step 1 models (a) and Step 2 models (b),
compared to that of CA125 and the Step 3 (pan-site) model in the within-one-year cases.
Black solid: CA125 alone; blue solid: Step 3 model; blue dotted: Panel D; blue dashed:
Panel C; red solid: Panel B; red dotted: Panel A; red dashed: Panel E. Note: Figure 2b
curves are based on validation set only.
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Table 2
Population characteristics of the samples
Race/Ethnic Group
Case
(N=118)
Control
(N=951)
White, Non-Hispanic 106 (89.8%) 872 (91.7%)
Black, Non-Hispanic 6 (5.1%) 47 (4.9%)
Hispanic 2 (1.7) 9 (0.9%)
Asian 3 (2.5%) 21 (2.2%)
American Indian 1 (0.8%) 2 (0.2%)
Age at Serum Draw
55–59 14 (11.9%) 120 (12.6%)
60–64 37 (31.4%) 295 (31%)
65–69 38 (32.2%) 304 (32%)
70–74 24 (20.3%) 192 (20.2%)
75–79 5 (4.2%) 40 (4.2%)
All 118 (100%) 951 (100%)
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Table 3
Characteristics of cases diagnosed within 2 years from blood draw (N=93)
Cancer type
≤12 months
N(%)
13–24 months
N(%)
Ovarian 48 (71.6) 23 (88.5)
Primary peritoneal 10 (14.9) 3 (11.5)
Fallopian tube 9 (13.4) 0 (0.0)
Histologic type
Serous cystadenocarcinoma 40 (59.7) 14 (53.8)
Mucinous cystadenocarcinoma 1 (1.5) 0 (0.0)
Endometrioid adenocarcinoma 7 (10.4) 5 (19.2)
Clear Cell Cystadenocarcinoma 3 (4.5) 1 (3.8)
Undifferentiated Carcinoma 1 (1.5) 0 (0.0)
Other 2 (3.0) 0 (0.0)
Adenocarcinoma, NOS/ Carcinoma, NOS 11 (16.4) 5 (19.2)
Malignant granulosa 2 (3.0) 1 (3.8)
Stage
Stage I/II 17 (25.4) 11 (42.3)
Stage III 42 (62.7) 9 (34.6)
Stage IV 8 (11.9) 5 (19.2)
Unknown 0 (0.0) 1 (3.8)
Grade
Well differentiated 2 (3.0) 3 (11.5)
Moderately differentiated 13 (19.4) 5 (19.2)
Poorly differentiated 41 (61.2) 14 (53.8)
Unknown 11 (16.4) 4 (15.4)
Mode of Detection
Screen Detected 49 (73.1) 1 (3.8)
 CA125+; TVU− 17 0
 CA125+; TVU+ 15 0
 CA125+; TVU not done 8 0
 CA125− TVU+ 9 1
Not Screen Detected 18 (26.9) 25 (96.2)
 CA125−; TVU− 9 16
 CA125−; TVU not done 7 8
CA125 not done; TVU not doneߓ 2 1
Total 67 26
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Table 5
Direct comparison of Step 1 and Step 2 model results* for the ≤12 month cases
Model
Sensitivity at Fixed Specificity§ ROC AUC
Step 1 Step 2 Step 1 Step 2
A 36.7 36.7 0.753 0.852†
B 86.7 80.0
C 33.3 46.7 0.754 0.848†
D 55.2 51.7 0.899† 0.810
E 37.9 36.7
*
Both Step 1 and Step 2 results are restricted to validation set only to facilitate direct comparison.
§
Specificity fixed at 98% (in both steps) for panels A, C, and D. For panel B, specificity was fixed (in both steps) at 92.2%, the level of the B2
model, while for panel E specificity was fixed (in both steps) at 91.1%, the level of the E1 model for the validation set.
†
Significantly elevated compared to model in other Step (p < 0.05)
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